CD8A and neoplasm: TAM blockade enhances the anti-tumour immunity of CD8+ CTLs and augments the efficacy of the PD-1 inhibitor [140,141]; it may also inhibit pro-tumour immune evasion, enhance the anti-tumour immunity of CD8+ CTLs and augment the efficacy of PD-1 inhibitor [142,143].